Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Non Operating Income: 2014-2025

Historic Non Operating Income for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to $5,000.

  • CytomX Therapeutics' Non Operating Income rose 171.43% to $5,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $14,000, marking a year-over-year increase of 227.27%. This contributed to the annual value of -$38,000 for FY2024, which is 26.67% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Non Operating Income of $5,000 as of Q3 2025, which was down 70.59% from $17,000 recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Non Operating Income peaked at $296,000 during Q2 2022, and registered a low of -$82,000 during Q2 2021.
  • Over the past 3 years, CytomX Therapeutics' median Non Operating Income value was -$2,000 (recorded in 2024), while the average stood at -$3,273.
  • Per our database at Business Quant, CytomX Therapeutics' Non Operating Income crashed by 1,740.00% in 2021 and then skyrocketed by 950.00% in 2025.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' Non Operating Income stood at $7,000 in 2021, then slumped by 85.71% to $1,000 in 2022, then spiked by 800.00% to $9,000 in 2023, then plummeted by 311.11% to -$19,000 in 2024, then spiked by 171.43% to $5,000 in 2025.
  • Its Non Operating Income stands at $5,000 for Q3 2025, versus $17,000 for Q2 2025 and $11,000 for Q1 2025.